SI2594279T1 - Tissue protective peptides and their uses - Google Patents
Tissue protective peptides and their uses Download PDFInfo
- Publication number
- SI2594279T1 SI2594279T1 SI200632230T SI200632230T SI2594279T1 SI 2594279 T1 SI2594279 T1 SI 2594279T1 SI 200632230 T SI200632230 T SI 200632230T SI 200632230 T SI200632230 T SI 200632230T SI 2594279 T1 SI2594279 T1 SI 2594279T1
- Authority
- SI
- Slovenia
- Prior art keywords
- disease
- isolated
- polypeptide
- isolated polypeptide
- amino acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 28
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 23
- 230000002669 organ and tissue protective effect Effects 0.000 title claims 2
- 229920001184 polypeptide Polymers 0.000 claims abstract 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 206010021143 Hypoxia Diseases 0.000 claims abstract 2
- 210000003169 central nervous system Anatomy 0.000 claims abstract 2
- 230000006378 damage Effects 0.000 claims abstract 2
- 238000012217 deletion Methods 0.000 claims abstract 2
- 230000037430 deletion Effects 0.000 claims abstract 2
- 230000007954 hypoxia Effects 0.000 claims abstract 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000001681 protective effect Effects 0.000 claims 4
- 238000010171 animal model Methods 0.000 claims 3
- 230000001413 cellular effect Effects 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 206010063094 Cerebral malaria Diseases 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 230000004224 protection Effects 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000021235 carbamoylation Effects 0.000 claims 1
- 230000003833 cell viability Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004295 hippocampal neuron Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000035322 succinylation Effects 0.000 claims 1
- 238000010613 succinylation reaction Methods 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 11
- 201000010099 disease Diseases 0.000 abstract 7
- 208000035475 disorder Diseases 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 208000014674 injury Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000006306 Cor pulmonale Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000006371 metabolic abnormality Effects 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 210000004994 reproductive system Anatomy 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70574105P | 2005-08-05 | 2005-08-05 | |
| US70627605P | 2005-08-08 | 2005-08-08 | |
| US83173706P | 2006-07-18 | 2006-07-18 | |
| EP12175366.9A EP2594279B1 (en) | 2005-08-05 | 2006-08-07 | Tissue protective peptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2594279T1 true SI2594279T1 (en) | 2018-04-30 |
Family
ID=37728020
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200632230T SI2594279T1 (en) | 2005-08-05 | 2006-08-07 | Tissue protective peptides and their uses |
| SI200632233T SI2540309T1 (en) | 2005-08-05 | 2006-08-07 | Tissue protective peptides and their uses |
| SI200631979T SI2371855T1 (sl) | 2005-08-05 | 2006-08-07 | Peptidi, ki ščitijo tkiva, in načini njihove uporabe |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200632233T SI2540309T1 (en) | 2005-08-05 | 2006-08-07 | Tissue protective peptides and their uses |
| SI200631979T SI2371855T1 (sl) | 2005-08-05 | 2006-08-07 | Peptidi, ki ščitijo tkiva, in načini njihove uporabe |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US8071554B2 (enExample) |
| EP (5) | EP2540309B1 (enExample) |
| JP (6) | JP5274253B2 (enExample) |
| KR (7) | KR20180067735A (enExample) |
| CN (2) | CN101378772B (enExample) |
| AU (1) | AU2006278264B2 (enExample) |
| BR (1) | BRPI0614529A8 (enExample) |
| CA (3) | CA2982909A1 (enExample) |
| DK (3) | DK2594279T3 (enExample) |
| EA (1) | EA015672B1 (enExample) |
| ES (3) | ES2653790T3 (enExample) |
| HU (3) | HUE035793T2 (enExample) |
| IL (3) | IL189287A (enExample) |
| IN (1) | IN2014CN02050A (enExample) |
| LT (2) | LT2540309T (enExample) |
| MX (3) | MX364100B (enExample) |
| NO (1) | NO20081112L (enExample) |
| NZ (1) | NZ565937A (enExample) |
| PL (3) | PL2540309T3 (enExample) |
| PT (3) | PT2371855E (enExample) |
| SG (2) | SG10201805825SA (enExample) |
| SI (3) | SI2594279T1 (enExample) |
| UA (1) | UA100222C2 (enExample) |
| WO (1) | WO2007019545A2 (enExample) |
| ZA (1) | ZA201101890B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| US9585932B2 (en) * | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
| US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| PT2371855E (pt) | 2005-08-05 | 2015-11-03 | Araim Pharmaceuticals Inc | Péptidos protetores de tecidos e suas utilizações |
| CA2654154A1 (en) * | 2006-06-07 | 2007-12-13 | The University Of Tokushima | Treatment of ischemic diseases using erythropoietin |
| DK2081956T3 (da) * | 2006-11-13 | 2013-06-24 | Charite Universitaetsmedizin | FREMGANGSMÅDE TIL CELLEDYRKNING OG FREMGANGSMÅDE TIL BEHANDLING OMFATTENDE EN vEPO-PROTEINVARIANT |
| AU2016203452B2 (en) * | 2008-01-22 | 2018-02-22 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| AU2014203195B2 (en) * | 2008-01-22 | 2016-03-31 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| SG10201604530SA (en) * | 2008-01-22 | 2016-07-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| US8791234B2 (en) * | 2010-10-14 | 2014-07-29 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
| US9566349B2 (en) * | 2010-10-14 | 2017-02-14 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
| CN102180948A (zh) * | 2011-03-03 | 2011-09-14 | 复旦大学附属中山医院 | 一种具有肾脏保护作用的短肽及其制备方法和应用 |
| CN102212111B (zh) * | 2011-05-05 | 2014-04-30 | 中国人民解放军第三军医大学 | 小分子多肽和小分子多肽脂质体及其运用 |
| CA2843014C (en) * | 2011-07-27 | 2020-01-21 | Neumedicines, Inc. | Use of il-12 to generate endogenous erythropoietin |
| US20140249573A1 (en) * | 2011-09-20 | 2014-09-04 | A.A. Cash Technology Ltd. | Methods and devices for occluding blood flow to an organ |
| KR101148191B1 (ko) * | 2011-09-27 | 2012-05-23 | 김후정 | 에리스로포이에틴-유래 펩타이드 및 그 용도 |
| WO2013158871A1 (en) | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of erythropoietin and derivatives for treating hypertension |
| KR20160052537A (ko) * | 2013-07-17 | 2016-05-12 | 아라임 파마슈티칼즈, 인크. | 조직 손상과 연관된 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
| CN104744593A (zh) * | 2013-12-25 | 2015-07-01 | 深圳先进技术研究院 | 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用 |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| KR20150130616A (ko) * | 2014-05-13 | 2015-11-24 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
| CN105837662A (zh) * | 2014-06-22 | 2016-08-10 | 马恒标 | 组织保护活性多肽sl3及其应用 |
| MX391259B (es) | 2015-10-14 | 2025-03-21 | X Therma Inc | Composiciones y métodos para reducir la formación de cristales de hielo. |
| JP2019523633A (ja) | 2016-04-29 | 2019-08-29 | アライム ファーマシューティカルズ，インコーポレーテッド | 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド |
| US10456346B2 (en) | 2016-11-10 | 2019-10-29 | Asc Regenity Ltd. | Cosmetic formulations for topical applications containing erythropoietin-derived molecules |
| KR101965814B1 (ko) | 2017-02-27 | 2019-08-13 | 재단법인 대구경북과학기술원 | 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용 |
| US11260101B2 (en) | 2017-02-28 | 2022-03-01 | Jinan University | Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof |
| CN108503690B (zh) * | 2017-02-28 | 2020-07-03 | 暨南大学 | 一种促进创伤后组织修复与再生的修复肽及其应用 |
| EP3761959A4 (en) * | 2018-04-08 | 2022-03-02 | Brim Biotechnology, Inc. | APPLICATION OF PEDF DERIVED SHORT PEPTIDES IN TENDON HEALING |
| KR102300060B1 (ko) | 2018-06-12 | 2021-09-08 | 주식회사 엘지에너지솔루션 | 2열 터미널 구조의 pcb 다이렉트 커넥터 |
| CN120267815A (zh) | 2018-09-10 | 2025-07-08 | 冷泉港实验室 | 用于治疗胰腺炎的方法 |
| CN112390877B (zh) * | 2019-08-16 | 2022-10-04 | 董红燕 | Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用 |
| CN118255845B (zh) * | 2022-12-27 | 2025-07-11 | 上海瑞吉康生物医药有限公司 | 相分离逆转多肽的变体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| US4558006A (en) | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US5498694A (en) | 1989-05-25 | 1996-03-12 | La Jolla Cancer Research Foundation | Peptides of the cytoplasmic domain of integrin |
| DE3924746A1 (de) | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
| WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US6140120A (en) * | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
| US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
| US5700909A (en) | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
| US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
| WO1995021919A2 (en) * | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Protein having tpo activity |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
| EP0886648B8 (en) * | 1995-06-07 | 2004-03-03 | Ortho Pharmaceutical Corporation | Compounds and peptides that bind to the erythropoietin receptor |
| JP2001524944A (ja) * | 1997-03-05 | 2001-12-04 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 神経障害性疼痛の緩和方法 |
| US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| US7270809B2 (en) * | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
| PL352223A1 (en) * | 1999-04-13 | 2003-08-11 | Kenneth S Warren Inst | Modulation of excitable tissue function by peripherally administered erythropoietin |
| WO2001083548A1 (en) * | 2000-04-28 | 2001-11-08 | Effector Cell Institute | Novel derivative of cell chemotactic factor |
| AU2002233230B2 (en) * | 2000-12-20 | 2007-02-01 | F. Hoffmann-La Roche Ag | Erythropoietin conjugates |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| RU2003125654A (ru) * | 2001-02-06 | 2005-03-10 | Мерк Патент ГмбХ (DE) | Модифицированный эритропоэтин (еро) с уменьшенной иммуногенностью |
| DE60232870D1 (de) * | 2001-04-04 | 2009-08-20 | Genodyssee | Neue polynukleotide und polypeptide des erythropoietingens |
| KR100467751B1 (ko) * | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
| US7300915B2 (en) * | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
| CA2491567A1 (en) | 2002-07-01 | 2004-01-08 | The Kenneth S. Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
| KR100478455B1 (ko) | 2002-08-19 | 2005-03-22 | 삼성전자주식회사 | 전자렌지 |
| ZA200505423B (en) | 2002-09-09 | 2008-08-27 | Warren Pharmaceuticals Inc | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| EP1578432A4 (en) * | 2002-10-03 | 2008-07-30 | Epimmune Inc | HLA BINDING PEPTIDES AND USES THEREOF |
| JP2004305006A (ja) * | 2003-04-01 | 2004-11-04 | Japan Science & Technology Agency | 人工調製肺サーファクタント |
| CN103230415B (zh) * | 2003-04-25 | 2016-05-04 | 匹兹堡大学联邦制高等教育 | 用于促进和增强神经修复和再生的肌肉来源的细胞（mdc） |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| CN1882355A (zh) | 2003-09-09 | 2006-12-20 | 沃伦药品公司 | 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素 |
| KR20070008519A (ko) | 2003-09-29 | 2007-01-17 | 워렌 파마슈티칼즈 인코포레이티드 | 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인 |
| US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
| US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
| WO2007010552A2 (en) | 2005-03-17 | 2007-01-25 | Serum Institute Of India Limited | N- terminal peg conjugate of erythropoietin |
| US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| EP2377884A1 (en) | 2005-05-10 | 2011-10-19 | Neoloch Aps | Neuritogenic peptides |
| EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
| PT2371855E (pt) * | 2005-08-05 | 2015-11-03 | Araim Pharmaceuticals Inc | Péptidos protetores de tecidos e suas utilizações |
| ATE554186T1 (de) | 2007-11-29 | 2012-05-15 | Molecular Health Gmbh | Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung |
| SG10201604530SA (en) | 2008-01-22 | 2016-07-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| CA2725601A1 (en) * | 2008-04-28 | 2009-11-05 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
| WO2011022056A2 (en) | 2009-08-18 | 2011-02-24 | Medical College Of Georgia Research Institute, Inc. | PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF |
-
2006
- 2006-08-07 PT PT111631941T patent/PT2371855E/pt unknown
- 2006-08-07 ES ES12175366.9T patent/ES2653790T3/es active Active
- 2006-08-07 DK DK12175366.9T patent/DK2594279T3/en active
- 2006-08-07 IN IN2050CHN2014 patent/IN2014CN02050A/en unknown
- 2006-08-07 CA CA2982909A patent/CA2982909A1/en not_active Abandoned
- 2006-08-07 EP EP12175352.9A patent/EP2540309B1/en active Active
- 2006-08-07 KR KR1020187016750A patent/KR20180067735A/ko not_active Ceased
- 2006-08-07 SG SG10201805825SA patent/SG10201805825SA/en unknown
- 2006-08-07 KR KR1020177005579A patent/KR20170027868A/ko not_active Ceased
- 2006-08-07 MX MX2016004825A patent/MX364100B/es unknown
- 2006-08-07 UA UAA200802850A patent/UA100222C2/uk unknown
- 2006-08-07 PT PT121753529T patent/PT2540309T/pt unknown
- 2006-08-07 JP JP2008525285A patent/JP5274253B2/ja not_active Expired - Fee Related
- 2006-08-07 PL PL12175352T patent/PL2540309T3/pl unknown
- 2006-08-07 AU AU2006278264A patent/AU2006278264B2/en not_active Ceased
- 2006-08-07 KR KR1020197019568A patent/KR20190084136A/ko not_active Ceased
- 2006-08-07 PL PL11163194T patent/PL2371855T3/pl unknown
- 2006-08-07 NZ NZ565937A patent/NZ565937A/en not_active IP Right Cessation
- 2006-08-07 KR KR1020087005373A patent/KR101626153B1/ko not_active Expired - Fee Related
- 2006-08-07 LT LTEP12175352.9T patent/LT2540309T/lt unknown
- 2006-08-07 SG SG2014007868A patent/SG2014007868A/en unknown
- 2006-08-07 CA CA2618396A patent/CA2618396C/en not_active Expired - Fee Related
- 2006-08-07 SI SI200632230T patent/SI2594279T1/en unknown
- 2006-08-07 MX MX2014011168A patent/MX339613B/es unknown
- 2006-08-07 BR BRPI0614529A patent/BRPI0614529A8/pt not_active Application Discontinuation
- 2006-08-07 HU HUE12175352A patent/HUE035793T2/en unknown
- 2006-08-07 EP EP06801051A patent/EP1924276A4/en not_active Withdrawn
- 2006-08-07 CA CA3079319A patent/CA3079319A1/en not_active Abandoned
- 2006-08-07 EP EP12175366.9A patent/EP2594279B1/en active Active
- 2006-08-07 SI SI200632233T patent/SI2540309T1/en unknown
- 2006-08-07 LT LTEP12175366.9T patent/LT2594279T/lt unknown
- 2006-08-07 MX MX2008001509A patent/MX2008001509A/es active IP Right Grant
- 2006-08-07 ES ES12175352.9T patent/ES2653864T3/es active Active
- 2006-08-07 KR KR1020207016998A patent/KR20200072568A/ko not_active Ceased
- 2006-08-07 EP EP17202352.5A patent/EP3363451A1/en not_active Withdrawn
- 2006-08-07 DK DK11163194.1T patent/DK2371855T3/en active
- 2006-08-07 CN CN2006800348244A patent/CN101378772B/zh not_active Expired - Fee Related
- 2006-08-07 PT PT121753669T patent/PT2594279T/pt unknown
- 2006-08-07 HU HUE11163194A patent/HUE026444T2/en unknown
- 2006-08-07 WO PCT/US2006/031061 patent/WO2007019545A2/en not_active Ceased
- 2006-08-07 ES ES11163194.1T patent/ES2550055T3/es active Active
- 2006-08-07 KR KR1020137016015A patent/KR101713368B1/ko not_active Expired - Fee Related
- 2006-08-07 KR KR1020187030050A patent/KR20180116475A/ko not_active Ceased
- 2006-08-07 CN CN201310529242.5A patent/CN103724418B/zh not_active Expired - Fee Related
- 2006-08-07 SI SI200631979T patent/SI2371855T1/sl unknown
- 2006-08-07 HU HUE12175366A patent/HUE035655T2/en unknown
- 2006-08-07 DK DK12175352.9T patent/DK2540309T3/en active
- 2006-08-07 EP EP11163194.1A patent/EP2371855B1/en active Active
- 2006-08-07 US US11/997,898 patent/US8071554B2/en not_active Expired - Fee Related
- 2006-08-07 PL PL12175366T patent/PL2594279T3/pl unknown
- 2006-08-07 EA EA200800536A patent/EA015672B1/ru not_active IP Right Cessation
-
2008
- 2008-02-05 IL IL189287A patent/IL189287A/en active IP Right Grant
- 2008-03-03 NO NO20081112A patent/NO20081112L/no not_active Application Discontinuation
-
2011
- 2011-03-11 ZA ZA2011/01890A patent/ZA201101890B/en unknown
- 2011-10-20 US US13/278,131 patent/US8716245B2/en not_active Expired - Fee Related
-
2012
- 2012-04-16 US US13/448,345 patent/US8673861B2/en not_active Expired - Fee Related
-
2013
- 2013-02-15 JP JP2013027479A patent/JP5918155B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-08 US US14/248,030 patent/US9340598B2/en not_active Expired - Fee Related
-
2015
- 2015-02-04 JP JP2015020020A patent/JP6158235B2/ja not_active Expired - Fee Related
- 2015-02-10 US US14/618,873 patent/US20150152156A1/en not_active Abandoned
- 2015-06-29 IL IL239695A patent/IL239695A0/en active IP Right Grant
-
2016
- 2016-05-05 US US15/147,848 patent/US10100096B2/en not_active Expired - Fee Related
- 2016-06-08 JP JP2016114010A patent/JP6491621B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-03 JP JP2018071318A patent/JP2018134084A/ja active Pending
- 2018-08-23 IL IL261346A patent/IL261346A/en unknown
- 2018-09-25 US US16/141,724 patent/US20190016769A1/en not_active Abandoned
-
2020
- 2020-01-30 JP JP2020013151A patent/JP2020078317A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2594279T1 (en) | Tissue protective peptides and their uses | |
| DK2864360T3 (en) | TARGETED THERAPY | |
| JP2013126995A5 (enExample) | ||
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| US20160194368A1 (en) | Circular polynucleotides | |
| JP2009508471A5 (enExample) | ||
| WO2010135491A3 (en) | Fibroblast growth factor mutants having improved functional half-life and methods of their use | |
| ES2947311T3 (es) | Gen UBE3A modificado para un enfoque de terapia génica para el síndrome de Angelman | |
| ES2381497T3 (es) | Agonistas del receptor del neuropéptido-2 | |
| US20240368235A1 (en) | Disease Treatment Drug Based on Mesenchymal-Stem-Cell Mobilization | |
| CA3256996A1 (en) | SPECIFIC COCHLEAR AND/OR VESTIBULAR CELL PROMOTER AND ITS USE | |
| CA2692358A1 (en) | Recombinant human interferon-like proteins | |
| RU2005127076A (ru) | Пептидные ингибиторы токсинов, производные ll-37 | |
| EP3583117B1 (en) | In vitro method for fusing two or more cells, in vitro, method for delivering a gene of interest, and pharmaceutical composition for use in the treatment of a disease | |
| WO2020077010A1 (en) | Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders | |
| EP2270141A1 (en) | Partial peptide of lacritin | |
| JP7707071B2 (ja) | コラーゲン７組成物を産生するための系および方法 | |
| CN103254315A (zh) | 一种重组tat-manf融合蛋白及其应用 | |
| JP2009507474A5 (enExample) | ||
| JP2006505290A5 (enExample) | ||
| CN107530401B (zh) | 作为代谢病症的治疗剂的皮连蛋白 | |
| US20240424030A1 (en) | Compositions, systems, and methods related to transgenic hookworms as a drug production and delivery technology | |
| US20250368708A1 (en) | TREFOIL FACTOR 2/INTERFERON alpha2 FUSION PROTEIN AND APPLICATION THEREOF IN PREVENTION AND TREATMENT OF VIRAL INFECTIOUS DISEASES | |
| US12006511B2 (en) | Recombinant PD-L1 peptides and methods of use | |
| US20130052238A1 (en) | Gene delivery of oct4 and sirt1 and pharmaceutical compositions thereof |